The biochemical mechanisms that regulate the process of cancer metastasis are still poorly understood. Because kinases, and the signaling pathways they comprise, play key roles in regulation of many cellular processes, we used an unbiased RNAi in vitro screen and a focused cDNA in vivo screen against human kinases to identify those with previously undocumented roles in metastasis. We discovered that G-protein-coupled receptor kinase 3 (GRK3; or β-adrenergic receptor kinase 2) was not only necessary for survival and proliferation of metastatic cells, but also sufficient to promote primary prostate tumor growth and metastasis upon exogenous expression in poorly metastatic cells in mouse xenograft models. Mechanistically, we found that GRK3 stimulated angiogenesis, at least in part through down-regulation of thrombospondin-1 and plasminogen activator inhibitor type 2. Furthermore, GRK3 was found to be overexpressed in human prostate cancers, especially in metastatic tumors. Taken together, these data suggest that GRK3 plays an important role in prostate cancer progression and metastasis.
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functional screens | essential kinases | ADRBK2 | TSP-1 | PAI-2 M etastasis, and resultant organ failure, is responsible for more than 90% of cancer deaths (1) . However, the biochemical and molecular mechanisms that regulate tumor progression to the metastatic phenotype are still poorly understood, especially the control of survival and proliferation of metastatic cells (2, 3) . To form metastases, tumor cells need to complete a multistep process, including escape from primary tumor site, intravasation into circulation, and extravasation into secondary sites, where they must be able to survive and proliferate. Cells at these sites then progress from micrometastases to macrometastases through enhancement of angiogenesis and other processes (4, 5) . Recent studies have suggested that cell migration and invasion can occur effectively during early phases of primary tumor development (6) (7) (8) , and survival and proliferation of metastatic cells may be the rate-limiting step for what we often describe as metastasis (2, 3) . As such, the ability to initiate angiogenesis at the metastatic site could serve as a distinguishing functional feature between metastatic and nonmetastatic cells.
Our previous work has shown the value of comparing functional differences between closely related cell lines through RNAi screens (9) (10) (11) (12) . In this study, we performed RNAi screens to compare essential kinase profiles between paired highly metastatic and weakly metastatic human cancer cell lines, and identified kinases that are essential preferentially for highly metastatic cells. To prioritize these kinases for further studies, an orthotopic prostate metastasis model was then used to test the corresponding cDNAs in poorly metastatic cells. From these studies, we discovered that G-protein-coupled receptor kinase 3 (GRK3) is not only essential for survival and proliferation of metastatic cells in vitro and in vivo, but also is capable of promoting primary tumor growth and metastasis in a prostate tumor model. Identifying and studying essential kinases in this manner expands our understanding of pathways controlling survival and proliferation in metastatic cells and may ultimately lead to discovery of novel drug targets for metastasis.
Results

GRK3 Promotes Orthotopic Prostate Tumor Growth and Metastasis.
We first sought to identify human kinases that were essential for highly metastatic cells compared with matched poorly metastatic cells. As such, we performed primary arrayed RNAi screens by using a lentiviral library expressing ∼2,100 shRNAs against ∼440 human kinases on four pairs of human melanoma and prostate and colon cancer cell lines. After applying appropriate criteria to the results from primary and secondary screens as detailed in the SI Materials and Methods (Figs. S1 and S2), we identified 30 essential kinases whose roles in metastasis have heretofore gone largely unstudied.
Significance
Although the majority of cancer-related deaths are consequences of metastatic dissemination, the molecular and cellular forces that drive tumor cell dispersion are still poorly understood. To help identify new regulators that play critical roles in these processes, we screened for human kinases that are important for continued survival of metastatic cells. One kinase identified from these screens, the G-protein-coupled receptor kinase 3 (GRK3; or β-adrenergic receptor kinase 2), was found to have a key role in promoting prostate tumor growth and metastasis in mouse models through enhancing angiogenesis. Notably, GRK3 is overexpressed in human prostate metastatic tumors. Further studies on GRK3 and its pathways promise to expand our knowledge of cancer metastasis and also yield new cancer therapeutic targets.
To determine whether any of the 30 kinases had a role in tumorigenesis or metastasis, we performed an in vivo cDNA screen by using a poorly metastatic variant of the American Type Culture Collection PC3 cell line, the PC3M cells (confirmed by DNA fingerprinting; referred as PC3 cells hereafter) (13) . We grouped retroviruses for the cDNAs of the 30 kinase candidates randomly into two pools (15 kinases per pool), which were then used to infect PC3 cells. Naïve PC3 and PC3-GFP cells were used as the controls. Four populations of PC3 cells (naïve PC3, PC3-GFP; pool 1 and pool 2) were injected orthotopically into the prostate glands of four cohorts of SCID mice. Pool 1 consistently generated prostate tumors that were >30-fold larger than the naïve PC3 and PC3-GFP controls (Fig. 1A and Fig. S3 ). Therefore, we chose to focus on pool 1 and divided the 15 kinases in this pool into four subpools, one of which produced larger tumors than the other three subpools in next round. Genomic PCR on the tumors from this subpool identified GRK3 as the dominant gene (Fig. S4) . We confirmed the result by testing the four kinases in this subpool individually. Only tumors formed by GRK3 overexpressing cells grew consistently larger than PC3-GFP cells (n = 6-7; P = −3 × 10 6 ). Thus, we concluded that GRK3 was the major driver in promoting primary tumor growth in PC3 cells in these experiments.
To extend our observation in PC3 cells to other prostate cancer cell lines, we overexpressed GRK3 in DU145 and LNCaP prostate cancer cells and tested its effect in vivo (n = 3-5 mice). On average, tumors ectopically expressing GRK3 were between 2.4 and 8 times larger than control tumors ( Fig. 1 B and C) . Notably, when we extended the PC3 in vivo experiment to 12 wk postimplantation, five of seven mice bearing PC3-GRK3 cells developed lung metastases, and three mice also had lymph node metastases. Meanwhile none of the 20 mice bearing PC3 cells expressing GFP or three other genes tested concurrently developed lung or lymph node metastases (P = 0.0003 for lung metastasis and P = 0.01 for lymph node metastasis, Fisher exact test; Fig. 1 D and E).
GRK3 Is Essential for Proliferation of Human Metastatic Cells. Our previous experience suggested that an shRNA lentiviral titration experiment with several doses of virus is more informative for determining the quantitative differences in sensitivities to shRNA expression between cell lines (12) . Therefore, we performed GRK3 shRNA viral titration experiment on five pairs of tumor cell lines and observed that two GRK3 shRNAs (shRNA-1 in Fig. 2A and shRNA-2 in Fig. S5 ) targeting different regions of GRK3 mRNA clearly had preferential inhibitory effects on metastatic lines (WM266-4, SW620, and LN4 cells in particular). Importantly, although both shRNAs partially inhibited some poorly metastatic lines, these effects were mainly seen at higher viral titers. These findings served as confirmation for the initial shRNA screen and for the cDNA in vivo results described earlier.
To further confirm that GRK3 played an essential role in vivo, we transduced the highly metastatic LN4 prostate cancer cells with a tetracycline-inducible shRNA lentiviral vector. Induction of shRNA expression by doxycycline treatment in vitro inhibited proliferation in LN4 cells carrying GRK3 shRNA-1, but not in LN4 cells carrying scrambled control shRNA or an ineffective GRK3 shRNA-3 ( Fig. 2B) . Importantly, inhibitory GRK3 shRNA-1 led to efficient knockdown of GRK3 protein, whereas noninhibitory GRK3 shRNA-3 and scrambled control shRNA did not (Fig. 2B) . These results underscore the specificity of the GRK3 shRNA effects observed and mitigate against "off-target" effects of the shRNAs.
We then injected LN4 cells carrying scrambled control shRNA or GRK3 shRNA-1 into the prostate glands of SCID mice. Two weeks later, doxycycline was administrated via i.p. injection daily for 4 wk to induce shRNA expression. Tumor weights in mice injected with LN4 cells expressing doxycycline-induced GRK3 shRNA-1 were significantly smaller than those from mice injected with LN4 cells with doxycycline-induced scrambled shRNA (n = 7-8; P = 0.00024; Fig. 2C ). Histological examination revealed that prostate tumors from LN4 cells expressing GRK3 shRNA-1 were largely necrotic (Fig. 2D ). This confirmed the essential role of GRK3 for metastatic LN4 cells in vivo.
GRK3 Stimulates Angiogenesis in Vitro and in Vivo. We next sought to determine the mechanism by which GRK3 promotes primary tumor growth and metastasis. Strikingly, we observed no obvious differences in proliferation rate, migration, or invasion between PC3-GFP or PC3-GRK3 cells (Fig. 3 A and B) . To investigate potential mechanisms of GRK3, we performed microarray analysis to examine global changes in gene expression induced by GRK3 and identified 86 genes that were up-regulated or down-regulated by GRK3 by more than 1.5-fold. Interestingly, Gene Ontology analysis on the microarray data using the DAVID tool (The Database for Annotation, Visualization and Integrated Discovery) (14, 15) indicated that wound healing (13 genes; Table S1 ) was the only biological process enriched among these differentially expressed genes with (P < 0.05 after Bonferroni correction; false discovery rate of 0.01).
Because wound healing is closely linked to angiogenesis, a critical process for tumor growth and progression, we hypothesized that GRK3 promoted tumor growth and metastasis through enhancing angiogenesis (16) . We first sought to determine whether GRK3 directly affected endothelial cell migration, an essential step for angiogenesis. We observed that PC3-GRK3 cells stimulated endothelial cell migration fivefold greater than control PC3-GFP cells in vitro (Fig. 3C ). This suggests that GRK3 stimulates primary tumor growth and metastasis, at least in part, by stimulating angiogenesis.
We then analyzed the primary tumors generated by PC3-GRK3 and PC3-GFP cells for differences in angiogenesis. To this end, we performed microvessel density (MVD) analysis and examined endothelial cell proliferation. Consistent with the in vitro endothelial migration assays, we observed a significant difference in MVD between GRK3-expressing tumors and GFP control tumors (Fig. 3D) . Specifically, PC3-GRK3 tumors had an average MVD of 71.8 per square millimeter (range, 60.2-80.8 per square millimeter; SD, 7.8) compared with 42.8 per square millimeter (range, 28.1-58.9 per square millimeter; SD, 15.4) for PC3-GFP tumors (P = 0.011, Mann-Whitney test; Fig. 3D ). We then used another metric for tumor angiogenesis, vascular proliferation by costaining for CD31 and Ki-67 (17) . Consistent with the MVD analysis, we observed an increase in proliferating microvessels in the primary tumor and significantly also in the metastases formed by GRK3-expressing tumors (Fig. 3D) . Consistently, tumors from LN4 cells expressing GRK3 shRNA had strikingly fewer vessels than those tumors from LN4 cells expressing scramble control shRNA, as shown in Fig. 3E . These findings strongly suggest that GRK3 enhances tumor growth and metastasis by stimulating angiogenesis.
GRK3 Suppresses Expression of Antiangiogenesis Proteins Throm-
bospondin-1 and Plasminogen Activator Inhibitor 2. Among the 13 wound healing genes regulated by GRK3, we focused on two genes, thrombospondin-1 (TSP-1; THBS1) and plasminogen activator inhibitor 2 (PAI-2; SERPINB2). Each has been shown to profoundly inhibit angiogenesis in human tumors (18) (19) (20) (21) (22) . Realtime (RT) QPCR and Western analysis showed that GRK3 is expressed at a higher level in metastatic cell lines than their poorly metastatic parental cell lines, and expression of TSP-1 and PAI-2 were down-regulated by GRK3 (Fig. 4 A and B) . We then used a kinase dead mutant of GRK3 (K220R) (23, 24) and observed that GRK3 kinase activity was required for its repression of TSP-1 and PAI-2 (Fig. 4C) . Furthermore, shRNA-mediated silencing of GRK3 in PC3-GRK3 cells relieved the repression of TSP-1 and PAI-2 by GRK3 (Fig. 4D) . Strikingly, knocking down endogenous levels of GRK3 in PC3-GFP control cells also resulted in an increase in TSP-1 and PAI-2 (Fig. 4D) . Furthermore, when GRK3 was knocked down in LN4 cells, PAI-2 expression was also increased, further supporting the suppression of PAI-2 by GRK3 (Fig. S6) . These results indicate that GRK3 induces repression of antiangiogenic proteins TSP-1 and PAI-2, which is consistent with our observations that GRK3 stimulates angiogenesis in vitro and in vivo.
GRK3 Is Overexpressed in Human Malignant
Tumors. The preferential inhibitory effects of GRK3 shRNAs in human metastatic cells, taken together with the ability of GRK3 cDNA to promote xenograft tumor growth and metastasis, suggest that GRK3 may play a physiologically relevant role in promoting human cancer progression. To assess the role of GRK3 in human cancer, we performed immunohistochemistry (IHC) staining of GRK3 protein on a human prostate tumor tissue microarray. GRK3 was significantly stronger in carcinomas compared with benign prostatic hyperplasias (P < 0.0005, Kruskal-Wallis test). Among carcinomas, the strongest expression was observed in nonskeletal metastases (P = 0.001, Kruskal-Wallis test; Fig. 5 A-E and Table 1 ). The staining results using two different antibodies were equivalent, with a Spearman ρ of 0.65 (rank correlation). These results indicate that GRK3 expression correlates with visceral metastases and supports the experimental xenograft results presented earlier.
Furthermore, in the human prostate cancer patient series, there was a strong trend between GRK3 expression and glomeruloid microvascular proliferation (GMP; i.e., vascular nests, a marker of VEGF-A-driven angiogenesis) (25) with a P value of 0.08 by Pearson χ 2 test. Specifically, only 6% of patients with low GRK3 expression were positive for GMP, whereas 18% of patients with high GRK3 expression were positive for GMP ( Fig.  5F shows a representative GMP + tumor). These findings further confirm the in vitro and in vivo experimental results and the conclusion that GRK3 stimulates angiogenesis.
Discussion
We report here a previously undescribed role of GRK3 in prostate cancer metastasis. Our findings were the result of a combination of an unbiased shRNA library screen and subsequent validation in vitro and in vivo. Our results indicate that GRK3 is necessary for survival and proliferation of metastatic cells in culture. We confirmed that GRK3 remained essential for metastatic cells in vivo through inducible shRNA expression. Additionally, we demonstrated that GRK3 is also sufficient to promote primary prostate tumor growth and metastasis upon exogenous expression in poorly metastatic cells. Moreover, we have demonstrated that GRK3 is overexpressed in prostate cancers, especially in metastasis, suggesting that it may play physiologic roles in the progression of human prostate cancer. Of note, these findings represent a heretofore undocumented role for GRK3 in human prostate cancer progression.
GRK3 (or β-adrenergic receptor kinase 2) belongs to a subfamily of kinases called GRKs (26) (27) (28) . GRK3 is best known to phosphorylate the agonist-occupied form of β-adrenergic receptors, leading to desensitization of the receptors to their agonists (29, 30) . It has also been shown to regulate signaling and internalization of several other G-protein-coupled receptors (GPCR) (31, 32) . Although GRK3 has not been implicated in cancer metastasis, it has been shown to be down-regulated specifically in a subtype of glioblastoma (33) , suggesting a subtypeand tissue-specific role of GRK3, which may result from differences in GPCR profiles, tumorigenic pathways, or tumor microenvironment in different organs and cancer types.
We further found that GRK3 enhances angiogenesis through regulation of several genes involved in angiogenesis and microenvironment modulation, including TSP-1 and PAI-2 (or SERPINB2), both of which are down-regulated by GRK3. TSP-1 was the first identified endogenous inhibitor of angiogenesis (21) . It is a large glycoprotein (150 kDa) that binds to cell surface receptors CD36 and CD47 and inhibits endothelial proliferation and migration. Reduced expression of TSP-1 is an important component of the angiogenic switch, and decrease in its expression facilitates growth of several tumor types, including bladder, breast, and ovarian cancer, fibrosarcoma, and glioblastoma (18, 19, 22) . PAI-2 is one of the two major physiological inhibitors of urokinase plasminogen activator, which has been shown to promote invasion and metastasis in various cancer types (20) . Strikingly, a number of studies indicated that higher PAI-2 expression in tumors is linked with prolonged survival, decreased metastasis or decreased tumor size (20) . Because access to vasculature is a critical component to metastasis, kinases that increase the angiogenic potential of tumor cells would be expected to increase their metastatic potential as well. It is not clear which signaling pathways underlying GRK3 suppression of TSP-1 and PAI-2 expression, which we are actively investigating.
It is intriguing that GRK3 not only controlled survival and proliferation of metastatic cells, but also promoted primary prostate tumor growth and metastasis by enhancing angiogenesis. Such activity is not without precedent, as several oncogenes, such as Ras and Myc, have been shown to stimulate cellular proliferation as well as angiogenesis (34, 35) . Similarly, silencing a key regulator in angiogenesis such as GRK3 could lead to inhibition of cellular survival and proliferation in vitro and in vivo.
Finally, our experimental findings of the role of GRK3 in tumor progression were corroborated by examining human tumors via IHC staining of prostate cancer patient samples. These analyses confirmed that regulation of GRK3 expression was physiologically relevant to human prostate cancer progression. These results may lead to improved disease prognosis using GRK3 as a novel biomarker or part of a panel of biomarkers for prostate cancer progression. Ultimately, as kinases have proven to be successful drug targets, it is our hope that a selective GRK3 inhibitor may be developed as an effective therapy for patients with metastatic cancer. 5 . GRK3 was up-regulated in human metastatic prostate tumors and associated with elevated angiogenesis. IHC staining of GRK3 in benign and malignant prostatic tissues (A-E). Weak and focal staining in benign prostatic hyperplasia and negative luminal cells (A), comparable weak staining in localized prostate cancer (B), stronger staining in advanced castration resistant prostate cancer (C), skeletal metastasis around bone trabeculae demonstrating stronger staining (D), and soft tissue metastasis with the strongest staining observed in these tissue categories (E). This subgroup was significantly stronger than other carcinomas categories (P = 0.001). Magnification of 400×. (Scale bar: 50 μm.) (F) GMP, or vascular nest, by factor VIII staining in a prostate carcinoma (considered to represent VEGF-A-driven angiogenesis; magnification of 400×).
Materials and Methods
Primary shRNA screens targeting 440 human kinases on four pairs of poorly and highly metastatic human cancer cell lines were done with the optimal viral doses for each pair. For inducible shRNA expression in vivo, LN4 cells carrying inducible scrambled control shRNA or inducible GRK3 shRNA were injected into prostates of two cohorts of male ICR/SCID mice (Taconic). Two weeks later, doxycycline was administrated i.p. daily for 4 wk before the mice were killed and the tumor tissues were weighed. For orthotopic prostate cancer xenograft studies, prostate cancer cells transduced with pooled viruses for multiple kinase cDNAs or singular viruses for individual kinase cDNAs were established by blasticidin selection and then injected into the prostate gland of male ICR/SCID mice. The mice were killed 8 or 12 wk after injection to examine for tumor growth in prostates or in metastatic sites.
Microarray analysis and real time PCR for GRK3-regulating genes were done by using Illumina Ref8-v3 BeadChips and a Roche LightCycler 480 instrument.
To further assess the regulation of TSP-1 and PAI-2 protein expression by GRK3 via Western blotting, cell lysates were collected and subjected to SDS/PAGE analysis using antibodies against TSP-1, GRK3, PAI-2 or β-actin.
Migration and invasion of prostate cancer and endothelial were done using Corning Transwell Chambers and BD BioCoat-Matrigel Invasion Chambers, respectively, according to manufacturer guidance. Detection of micrometastases in lungs and livers of mice orthotopically injected with PC3-GFP or PC3-GRK3 cells were done through IHC staining by using anti-human cytokeratin antibody. Staining for microvessels and vascular proliferation was performed by dual IHC using a pan-endothelial marker CD34 rat anti-mouse antibody and Ki-67 rat anti-mouse antibody for endothelial cell proliferation (termed vascular proliferation). The average MVD in tumor tissue was assessed in accordance with the Weidner approach with minor modifications (36) .
To determine the protein expression patterns of GRK3 in human prostate cancer tissues, we stained formalin-fixed and paraffin-embedded human prostate tissues with GRK3. A staining index was calculated as a product of staining intensity and proportion of positive tumor cells. Associations between variables were assessed by Pearson χ 2 and Kruskal-Wallis tests. The SPSS statistical package (version 19.0; SPSS) was used. GMP, or vascular nests, a marker of VEGF-A-driven angiogenesis, were stained on human prostate tissues and recorded as previously reported (25) . Detailed experimental materials and procedures are described in SI Materials and Methods. 
